Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone in Recurrent or Persistent Endometrial Carcinoma
NCT00095979Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2005
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in endometrial adenocarcinoma, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate and Frequency and Severity of Observed Adverse Effects. Started May 2005; status: completed.
02
Drugs
ixabepilone
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT00095979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095979.